nirmatrelvir: component of COVID-19 drug Paxlovid [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Paxlovid : A mixture containing nirmatrelvir and ritonavir. It is co-administered in tablet form for the treatment and post-exposure prophylaxis of COVID-19. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
nirmatrelvir : An azabicyclohexane that is (1R,5S)-3-azabicyclo[3.1.0]hexane substituted by {(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}aminoacyl, 3-methyl-N-(trifluoroacetyl)-L-valinamide, methyl and methyl groups at positions 2S, 3, 6 and 6, respectively. It is the first orally administered inhibitor of SARS-CoV-2 main protease developed by Pfizer and used in combination with ritonavir for the treatment of COVID-19. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 155903259 |
| CHEMBL ID | 4802135 |
| CHEBI ID | 170007 |
| SCHEMBL ID | 24108848 |
| Synonym |
|---|
| pf07321332 |
| (1r,2s,5s)-n-{(1s)-1-cyano-2-[(3s)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[3-methyl-n-(trifluoroacetyl)-l-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide |
| CHEBI:170007 , |
| nirmatrelvir |
| pf 07321332 |
| AC-35259 |
| CHEMBL4802135 |
| science.abl4784, 6 |
| bdbm496902 |
| 870124 more info pf-00835231 |
| AT31194 |
| (1r,2s,5s)-n-[(1s)-1-cyano-2-[(3s)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2s)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide |
| paxlovid (nirmatrelvir + ritonavir) |
| example e61 [wo2021250648a1] |
| gtpl11503 |
| nirmatrelvir [who-dd] |
| nirmatrelvir [inn] |
| nirmatrelvir component of paxlovid |
| nirmatrelvir [jan] |
| nirmatrelvir [usan] |
| paxlovid component nirmatrelvir |
| 3-azabicyclo[3.1.0]hexane-2-carboxamide, n-[(1s)-1-cyano-2-[(3s)-2-oxo-3-pyrrolidinyl]ethyl]-3-[(2s)-3,3-dimethyl-1-oxo-2-[(2,2,2-trifluoroacetyl)amino]butyl]-6,6-dimethyl-, (1r,2s,5s)- |
| (1r,2s,5s)-n-{(1s)-1-cyano-2-[(3s)-2-oxopyrrolidin-3-yl]ethyl}-3-[(2s)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide |
| 7R9A5P7H32 , |
| (1r,2s,5s)-n-[(1s)-1-cyano-2-[(3s)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2s)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide |
| unii-7r9a5p7h32 |
| who 12161 |
| (1r,2s,5s)-n-((1s)-1-cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-6,6-dimethyl-3-(3-methyl-n-(trifluoroacetyl)-l-valyl)-3-azabicyclo(3.1.0)hexane-2-carboxamide |
| 3-azabicyclo(3.1.0)hexane-2-carboxamide, n-((1s)-1-cyano-2-((3s)-2-oxo-3-pyrrolidinyl)ethyl)-3-((2s)-3,3-dimethyl-1-oxo-2-((2,2,2-trifluoroacetyl)amino)butyl)-6,6-dimethyl-, (1r,2s,5s)- |
| (1S,3AS,4AR)-N-[(1S)-1-CYANO-2-[(3S)-2-OXOTETRAHYDRO-1H-PYRROL-3-YL]ETHYL]-2-[(2S)-3,3-DIMETHYL-1-OXO-2-[(TRIFLUOROACETYL)AMINO]BUTYL]-4,4-DIMETHYL-2,3,3A,4A-TETRAHYDRO-1H-CYCLOPROPA[1,2-C]PYRROLE-1-CARBOXAMIDE |
| 2628280-40-8 |
| pf-07321332 |
| EX-A5024 |
| pf07321332(nirmatrelvir) |
| paxlovid |
| CS-0166635 |
| DTXSID501336829 |
| EN300-28333908 |
| HY-138687 |
| SCHEMBL24108848 |
| Z4994097664 |
| (1r,2s,5s)-n-((s)-1-cyano-2-((s)-2-oxopyrrolidin-3-yl)ethyl)-3-((s)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide |
| sars-cov-2 3clpro inhibitor pf-07321332 |
| paxlovid component pf-07321332 |
| sars-cov-2-3cl protease inhibitor pf-07321332 |
| zgw , |
Nirmatrelvir (PF-07321332) is a nitrile-bearing small-molecule inhibitor that, in combination with ritonavir, is used to treat infections by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) The drug has the potential to facilitate negative conversion.
Nirmatrelvir/ritonavir has shown to reduce COVID-19 hospitalization and death before Omicron, but updated real-world evidence studies are needed.
| Excerpt | Reference |
|---|---|
| "Nirmatrelvir-ritonavir has been authorized for emergency use by many countries for the treatment of coronavirus disease 2019 (Covid-19). " | ( VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19. Bao, H; Cao, Z; Chen, P; Cui, Z; Feng, H; Gao, W; Gao, Y; Gui, H; Jiang, Y; Mei, S; Meng, X; Ning, G; Shi, Y; Song, Z; Sun, J; Wang, W; Xie, Q; Xu, Y; Zhang, Q; Zhang, Y; Zhao, R, 2023) |
| "Nirmatrelvir/ritonavir has shown to reduce COVID-19 hospitalization and death before Omicron, but updated real-world evidence studies are needed. " | ( Real-World Effectiveness of Nirmatrelvir/Ritonavir on Coronavirus Disease 2019-Associated Hospitalization Prevention: A Population-based Cohort Study in the Province of Quebec, Canada. Benigeri, M; Brosseau, M; Cauchon, M; Chapdelaine, H; Claveau, D; Diop, M; Dumaresq, J; Haddad, E; Kaboré, JL; Laffont, B; Luong, ML; Tardif, MR; Turgeon, AF, 2023) |
Nirmatrelvir/ritonavir treatment does not impede adaptive immune responses to SARS-CoV-2. Treatment significantly reduced oxygen therapy requirements in high-risk patients with COVID-19 during the omicron variant surge.
Molnupiravir and nirmatrelvir/ritonavir (NIR) were recently approved for the early treatment of COVID-19. Dysgeusia with a bitter or metallic taste is a common side effect. In terms of safety, although the incidence of any adverse events was higher in the NIR group.
| Excerpt | Reference |
|---|---|
| " To evaluate and quantify the DDIs between them and provide rational dose management strategies of BTK inhibitors, we conducted this study using physiologically-based pharmacokinetic (PBPK) models." | ( Drug-drug interactions and dose management of BTK inhibitors when initiating nirmatrelvir/ritonavir (paxlovid) based on physiologically-based pharmacokinetic models. Chen, L; Chen, W; Li, C; Li, L, 2023) |
| "Physicochemical properties and pharmacokinetic parameters were acquired from the published literature and databases." | ( Drug-drug interactions and dose management of BTK inhibitors when initiating nirmatrelvir/ritonavir (paxlovid) based on physiologically-based pharmacokinetic models. Chen, L; Chen, W; Li, C; Li, L, 2023) |
Co-administration of Bruton's tyrosine kinase (BTK) inhibitors with nirmatrelvir/ritonavir is challenging because of potential drug-drug interactions (DDIs) This case highlights the strong and important drug-Drug interaction between tacrolimus and nirmatservir.
| Excerpt | Reference |
|---|---|
| "This case highlights the strong and important drug-drug interaction between tacrolimus and nirmatrelvir/ritonavir leading to toxic levels of tacrolimus." | ( Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin. Carroll, E; McCabe, D; Sindelar, M, 2023) |
| " However, the use of NMV/r is complicated by significant drug-drug interactions (DDIs) with frequently prescribed medications." | ( Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir. Huang, X; Oon, HH; Quah, KSE; Renia, L, 2022) |
| "Co-administration of Bruton's tyrosine kinase (BTK) inhibitors with nirmatrelvir/ritonavir is challenging because of potential drug-drug interactions (DDIs)." | ( Drug-drug interactions and dose management of BTK inhibitors when initiating nirmatrelvir/ritonavir (paxlovid) based on physiologically-based pharmacokinetic models. Chen, L; Chen, W; Li, C; Li, L, 2023) |
The therapeutic approach involved a 5-day regimen of nirmatrelvir/ritonavir at a dosage of 300/100 mg administered twice daily. 16% requiring renal dosage adjustment.
| Role | Description |
|---|---|
| EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor | An EC 3.4.22.* (cysteine endopeptidase) inhibitor that interferes with the action of SARS coronavirus main proteinase (EC 3.4.22.69). |
| anticoronaviral agent | Any antiviral agent which inhibits the activity of coronaviruses. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| nitrile | A compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it. |
| pyrrolidin-2-ones | A pyrrolidinone in which the oxo group is at position 2 of the pyrrolidine ring. |
| secondary carboxamide | A carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1). |
| pyrrolidinecarboxamide | |
| tertiary carboxamide | A carboxamide resulting from the formal condensation of a carboxylic acid with a secondary amine; formula RC(=O)NHR(1)R(2). |
| organofluorine compound | An organofluorine compound is a compound containing at least one carbon-fluorine bond. |
| azabicyclohexane | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Replicase polyprotein 1ab | Human coronavirus 229E | IC50 (µMol) | 0.1450 | 0.0300 | 2.1441 | 9.5100 | AID1886839 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | IC50 (µMol) | 0.0471 | 0.0002 | 2.4585 | 9.9600 | AID1851889; AID1857869; AID1863303; AID1886838; AID1889751; AID1897956; AID1901756 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | Ki | 0.0031 | 0.0000 | 1.6307 | 9.0000 | AID1884567; AID1884824; AID1889778; AID1897967; AID1898063 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | EC50 (µMol) | 3.4000 | 0.0030 | 4.1105 | 9.8200 | AID1863306 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| double membrane vesicle viral factory outer membrane | Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1889759 | Inhibition of SARS-CoV-2 main protease G15S mutant expressed in Escherichia coli BL21 (DE3) at 5 nM using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis re | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1889771 | Inhibition of SARS-CoV-2 main protease L205V mutant expressed in Escherichia coli BL21 (DE3) at 20 nM using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1857880 | Antiviral activity against SARS CoV-2 delta TY11-927 infected in HEK293T cells transfected with ACE2 and TMPRSS2 assessed as inhibition of virus induced cytopathic effect incubated for 2 to 3 days by MTT assay | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease. |
| AID1889758 | Inhibition of wild type SARS-CoV-2 main protease expressed in Escherichia coli BL21 (DE3) at 5 nM using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis rela | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1889768 | Inhibition of SARS-CoV-2 main protease L89F mutant expressed in Escherichia coli BL21 (DE3) at 20 nM using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis r | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1889762 | Inhibition of SARS-CoV-2 main protease K90R mutant expressed in Escherichia coli BL21 (DE3) at 5 nM using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis re | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1884827 | Binding affinity to HKU1-CoV main protease by FRET assay | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir. |
| AID1884568 | Antiviral activity against SARS COV-2 | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease. |
| AID1884567 | Inhibition of SARS CoV-2 main protease | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease. |
| AID1889755 | Inhibition of SARS-CoV-2 main protease K90R mutant expressed in Escherichia coli BL21 (DE3) using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1857883 | Cytotoxicity against HEK293T cells transfected with ACE2 and TMPRSS2 assessed as reduction in cell viability | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease. |
| AID1889753 | Inhibition of SARS-CoV-2 main protease T21I mutant expressed in Escherichia coli BL21 (DE3) using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1889770 | Inhibition of SARS-CoV-2 main protease P132H mutant expressed in Escherichia coli BL21 (DE3) at 20 nM using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1889765 | Inhibition of wild type SARS-CoV-2 main protease expressed in Escherichia coli BL21 (DE3) at 20 nM using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis rel | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1889760 | Inhibition of SARS-CoV-2 main protease T21I mutant expressed in Escherichia coli BL21 (DE3) at 5 nM using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis re | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1863303 | Inhibition of His/SUMO tagged SARS-CoV2 main protease expressed in Escherichia coli BL21 (DE3) cells using DABCYL-Lys-Thr-Ser-Ala-Val-Leu-Gln-Ser-Gly-Phe-Arg-Lys-Met-Glu-EDANS as fluorogenic substrate preincubated for 30 mins followed by substrate additio | 2022 | European journal of medicinal chemistry, Oct-05, Volume: 240 | A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals. |
| AID1851889 | Inhibition of SARS-CoV-2 main protease using MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 as fluorescent substrate preincubated for 10 mins followed by substrate addition and measured every 10 sec for 10 mins by FRET assay | 2022 | Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19 | Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity. |
| AID1889772 | Inhibition of wild type SARS-CoV-2 main protease expressed in Escherichia coli BL21 (DE3) at 100 nM using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis re | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1857878 | Antiviral activity against wild type SARS CoV-2 infected in HEK293T cells transfected with ACE2 and TMPRSS2 assessed as inhibition of virus induced cytopathic effect incubated for 2 to 3 days by MTT assay | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease. |
| AID1889773 | Inhibition of SARS-CoV-2 main protease G15S mutant expressed in Escherichia coli BL21 (DE3) at 100 nM using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1857887 | Antiviral activity against SARS CoV infected in HEK293T cells transfected with ACE2 and TMPRSS2 assessed as inhibition of virus induced cytopathic effect incubated for 2 to 3 days by MTT assay | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease. |
| AID1889752 | Inhibition of SARS-CoV-2 main protease G15S mutant expressed in Escherichia coli BL21 (DE3) using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1857901 | Inhibition of SARS-CoV-2 3CLpro spiked in human A-431 cells assessed as decrease in fluorescence intensity at 0.5 uM incubated for 30 mins in presence of N-((S)-1-{2-[(R)-2-Chloro-2-fluoroacetyl]-2-{[(S)-2-oxopyrrolidin-3-yl]methyl}hydrazineyl}-4-methyl-1 | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease. |
| AID1889761 | Inhibition of SARS-CoV-2 main protease L89F mutant expressed in Escherichia coli BL21 (DE3) at 5 nM using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis re | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1889751 | Inhibition of wild type SARS-CoV-2 main protease expressed in Escherichia coli BL21 (DE3) using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1889766 | Inhibition of SARS-CoV-2 main protease G15S mutant expressed in Escherichia coli BL21 (DE3) at 20 nM using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis r | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1889754 | Inhibition of SARS-CoV-2 main protease L89F mutant expressed in Escherichia coli BL21 (DE3) using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1863315 | Antiviral activity against SARS-CoV2 infected in human A549-ACE2 cells assessed as reduction in virus-induced cytopathic effect by flow cytometry analysis | 2022 | European journal of medicinal chemistry, Oct-05, Volume: 240 | A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals. |
| AID1886838 | Inhibition of full length SARS-CoV-2 3CLpro expressed in Escherichia coli BL21 (DE3) cells using (DABCYL)KTSAVLQSGFRKM(Glu)(EDANS) peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 1.5 hrs by FRET assay | 2022 | ACS medicinal chemistry letters, Aug-11, Volume: 13, Issue:8 | A Warhead Substitution Study on the Coronavirus Main Protease Inhibitor Nirmatrelvir. |
| AID1889756 | Inhibition of SARS-CoV-2 main protease P132H mutant expressed in Escherichia coli BL21 (DE3) using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1889776 | Inhibition of SARS-CoV-2 main protease K90R mutant expressed in Escherichia coli BL21 (DE3) at 100 nM using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1857881 | Antiviral activity against SARS CoV-2 omicron TY38-873 BA.1 variant infected in HEK293T cells transfected with ACE2 and TMPRSS2 assessed as inhibition of virus induced cytopathic effect incubated for 2 to 3 days by MTT assay | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease. |
| AID1857886 | Cytotoxicity against African green monkey Vero E6 cells transfected with TMPRSS2 assessed as reduction in cell viability | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease. |
| AID1889757 | Inhibition of SARS-CoV-2 main protease L205V mutant expressed in Escherichia coli BL21 (DE3) using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1889774 | Inhibition of SARS-CoV-2 main protease T21I mutant expressed in Escherichia coli BL21 (DE3) at 100 nM using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1857879 | Antiviral activity against SARS CoV-2 alpha QK002 infected in HEK293T cells transfected with ACE2 and TMPRSS2 assessed as inhibition of virus induced cytopathic effect incubated for 2 to 3 days by MTT assay | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease. |
| AID1857884 | Antiviral activity against wild type SARS CoV-2 infected in Vero E6 cells transfected with TMPRSS2 assessed as inhibition of virus induced cytopathic effect incubated for 2 to 3 days by MTT assay | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease. |
| AID1897956 | Inhibition of SARS-CoV-2 main protease using MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 as substrate preincubated for 30 mins followed by substrate addition and measured every 10 sec for 10 mins by FRET assay | 2022 | Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24 | Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors. |
| AID1898063 | Inhibition of N-terminal His6-tagged SARS-CoV2 Wuhan-Hu-1 main protease expressed in Escherichia coli using Dabcyl-KTSAVLQSGFRKME-Edans as substrate incubated for 60 mins by microplate reader analysis | 2022 | Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24 | Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2. |
| AID1889750 | Inhibition of SARS-CoV-2 main protease L205V mutant expressed in Escherichia coli BL21 (DE3) at 100 nM using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1857882 | Antiviral activity against SARS CoV-2 omicron TY38-873 BA.2 variant infected in HEK293T cells transfected with ACE2 and TMPRSS2 assessed as inhibition of virus induced cytopathic effect incubated for 2 to 3 days by MTT assay | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease. |
| AID1827045 | Antiviral activity against SARS Cov-2 infected in Vero E6 cells expressing hACE2 assessed as virus induced cytopathic effect incubated for 3 day by Cell Titer-Glo assay | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Novel Nitrile Peptidomimetics for Treating COVID-19. |
| AID1889769 | Inhibition of SARS-CoV-2 main protease K90R mutant expressed in Escherichia coli BL21 (DE3) at 20 nM using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis r | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1857885 | Antiviral activity against wild type SARS CoV-2 infected in Vero E6 cells transfected with TMPRSS2 assessed as inhibition of virus induced cytopathic effect incubated for 2 to 3 days in presence of P-gp inhibitor CP-100356 by MTT assay | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease. |
| AID1889764 | Inhibition of SARS-CoV-2 main protease L205V mutant expressed in Escherichia coli BL21 (DE3) at 5 nM using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis r | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1897968 | Antiviral activity against SARS-CoV-2 infected in Vero E6 cells assessed as reduction in virus induced cytopathic effect incubated for 3 days | 2022 | Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24 | Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors. |
| AID1863307 | Antiviral activity against SARS-CoV2 USA-WA1/2020 infected in African green monkey Vero E6 cells assessed as reduction in viral plaques incubated for 3 days by plaque reduction neutralization test | 2022 | European journal of medicinal chemistry, Oct-05, Volume: 240 | A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals. |
| AID1857889 | Antiviral activity against HCoV-OC43 infected in HEK293T cells transfected with ACE2 and TMPRSS2 assessed as inhibition of virus induced cytopathic effect incubated for 2 to 3 days by MTT assay | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease. |
| AID1886840 | Antiviral activity against against Human coronavirus 229E infected in human MRC5 cells assessed as reduction in cell viability measured after 4 days by CellTiter-Glo luminescence assay | 2022 | ACS medicinal chemistry letters, Aug-11, Volume: 13, Issue:8 | A Warhead Substitution Study on the Coronavirus Main Protease Inhibitor Nirmatrelvir. |
| AID1889777 | Inhibition of SARS-CoV-2 main protease P132H mutant expressed in Escherichia coli BL21 (DE3) at 100 nM using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1889778 | Inhibition of wild type SARS-CoV-2 main protease expressed in Escherichia coli BL21 (DE3) assessed as inhibition constant using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 20 mins followed by substrate addition by FRET analysis | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1897958 | Antiviral activity against SARS-CoV-2 infected in Vero E6 cells preincubated for 1 hr followed by methylcellulose addition and measured after 25 to 26 hrs by EliSpot reader based analysis | 2022 | Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24 | Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors. |
| AID1884826 | Binding affinity to MERS-CoV main protease by FRET assay | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir. |
| AID1863306 | Inhibition of eGFP fused SARS-CoV2 main protease transfected in HEK293T/17 cells incubated for 72 hrs by fluorescence based flow cytometry analysis | 2022 | European journal of medicinal chemistry, Oct-05, Volume: 240 | A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals. |
| AID1897967 | Inhibition of SARS-CoV-2 main protease expressed in Escherichia coli using Dabcyl-KTSAVLQSGFRKME-Edans as substrate incubated for 60 mins by FRET based assay | 2022 | Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24 | Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors. |
| AID1901756 | Inhibition of SARS-CoV-2 3CL protease using MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 fluorogenic peptide as substrate incubated for 30 mins and measured by FRET assay | 2022 | European journal of medicinal chemistry, Mar-05, Volume: 231 | In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease. |
| AID1889775 | Inhibition of SARS-CoV-2 main protease L89F mutant expressed in Escherichia coli BL21 (DE3) at 100 nM using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1889767 | Inhibition of SARS-CoV-2 main protease T21I mutant expressed in Escherichia coli BL21 (DE3) at 20 nM using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis r | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1889763 | Inhibition of SARS-CoV-2 main protease P132H mutant expressed in Escherichia coli BL21 (DE3) at 5 nM using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins by FRET analysis r | 2022 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 62 | Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. |
| AID1884825 | Binding affinity to NL63-CoV main protease by FRET assay | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir. |
| AID1897955 | Inhibition of SARS-CoV-2 main protease at 10 uM using MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 as substrate preincubated for 30 mins followed by substrate addition and measured every 10 sec for 10 mins by FRET assay relative to control | 2022 | Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24 | Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors. |
| AID1897959 | Cytotoxicity against african green monkey Vero E6 cells assessed as reduction in cell viability after 26 hrs by MTS assay | 2022 | Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24 | Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors. |
| AID1884824 | Binding affinity to SARS CoV-2 main protease by FRET assay | 2022 | Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13 | Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir. |
| AID1857888 | Antiviral activity against MERS-CoV EMC2012 infected in HEK293T cells transfected with DPP4 assessed as inhibition of virus induced cytopathic effect incubated for 2 to 3 days by MTT assay | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease. |
| AID1857869 | Inhibition of recombinant full length SARS-CoV-2 3CLpro expressed in Escherichia coli using Ac-Abu-Tle-Leu-Gln-MCA as fluorogenic substrate preincubated for 30 mins followed by substrate addition and measured for 6 hrs by multimode plate reader analysis | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease. |
| AID1886839 | Inhibition of full length C terminal His-tagged Human coronavirus 229E 3CLpro expressed in Escherichia coli Rosetta (DE3) cells using (DABCYL)KTSAVLQSGFRKM(Glu)(EDANS) peptide as substrate preincubated for 30 mins followed by substrate addition and measur | 2022 | ACS medicinal chemistry letters, Aug-11, Volume: 13, Issue:8 | A Warhead Substitution Study on the Coronavirus Main Protease Inhibitor Nirmatrelvir. |
| AID1863314 | Antiviral activity against SARS-CoV2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect incubated for 3 days in the presence of CP-100356 by flow cytometry analysis | 2022 | European journal of medicinal chemistry, Oct-05, Volume: 240 | A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals. |
| AID1827044 | Inhibition of full length SARS-CoV-2 3CL protease using Dabcyl-KTSAVLQ-SGFRKME-Edans fluorogenic peptide as substrate by FRET assay | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Novel Nitrile Peptidomimetics for Treating COVID-19. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 182 (100.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (2.66%) | 5.53% |
| Reviews | 24 (12.77%) | 6.00% |
| Case Studies | 15 (7.98%) | 4.05% |
| Observational | 8 (4.26%) | 0.25% |
| Other | 136 (72.34%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||